RHA Dynamic Volume Cleared for Midface — Revance Expands Indication Beyond Nasolabial Folds

The midface indication is strategically important because it positions RHA as a competitor to Juvéderm Voluma and Restylane Lyft in the high-value volumization space. Midface cases typically command premium pricing and drive patient satisfaction when executed well. RHA's dynamic-movement profile appeals to patients seeking natural-looking results, and the indication gives prescribers a cleared pathway for midface work. For practices: RHA Dynamic Volume now competes directly with AbbVie and Galderma in the volumization category, not just in fine-line correction. Pricing and rebate structures through Evolus's distribution network will determine adoption velocity. The competitive intensity in volumizers—where per-syringe margins are already compressed—will likely tighten further.